nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.02.2016 | Review Article

Mal de Meleda: A Focused Review

verfasst von: Caroline Perez, Amor Khachemoune

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Mal de Meleda is a rare autosomal recessive palmoplantar keratoderma (PPK) disease with an estimated prevalence of 1:100,000. Clinically, the onset of the disease is typically soon after birth and features a transgrediens (plantar surface progressing to dorsal surface) and progrediens (worsening with age) pattern of hyperkeratosis of the palms and soles. The disease can feature other potentially disfiguring effects on the hands and feet that can severely impact function. Histologically, the lesions show hyperkeratosis and acanthosis without epidermolysis in the epidermis, accompanied by perivascular lymphocytic infiltrate in the dermis. Secreted LY6/urokinase-type plasminogen activator receptor (uPAR)-related protein-1 (SLURP-1) genetic mutations are implicated in Mal de Meleda. SLURP-1 is involved in mediation of inflammation as well as keratinocyte apoptosis regulation. Because the disease is so rare, there are no set guidelines for management, but the accepted approach tends to include oral acitretin plus topical keratolytic therapy. Genetic counseling should also be offered. This focused review highlights the clinical and histological features, differential diagnoses, genetic background, and the current thoughts on management of Mal de Meleda.

Fatović-Ferencić S, Holubar K. The portrait and paper of a forgotten hero—Luca Stulli (1772–1828) and the Mal de Meleda of yesteryear: a 175-year anniversary. J Invest Dermatol. 2001;116:198–9.PubMedCrossRef

Bakija-Konsuo A. Mal de Meleda—through history and today. Acta Dermatovenerol Croat. 2014;22(2):79–84.PubMed

Saftić V, Rudan D, Zgaga L. Mendelian diseases and conditions in Croatian island populations: historic records and new insights. Croat Med J. 2006;47:543–52.PubMedPubMedCentral

Fischer J, Bouadjar B, Heilig R, et al. Genetic linkage of Meleda disease to chromosome 8qter. Eur J Hum Genet. 1998;6:542–7.PubMedCrossRef

Bchetnia M, Laroussi N, Youssef M, et al. Particular Mal de Meleda phenotypes in Tunisia and mutations founder effect in the Mediterranean region. Biomed Res Int. 2013;2013:206803. doi:10.1155/2013/206803 PubMedPubMedCentralCrossRef

Oh YJ, Lee HE, Ko JY, et al. A sporadic case of Mal de Meleda caused by gene mutation in SLURP-1 in Korea. Ann Dermatol. 2011;23(3):396–9.PubMedPubMedCentralCrossRef

Zhao L, Vahlquist A, Virtanen M, et al. Palmoplantar keratoderma of the Gamborg-Nielsen type is caused by mutations in the SLURP1 gene and represents a variant of Mal de Meleda. Acta Derm Venereol. 2014;94(6):707–10.PubMedCrossRef

Nellen RG, Steijlen PM, Hennies HC, et al. Haplotype analysis in western European patients with mal de Meleda: founder effect for the W15R mutation in the SLURP1 gene. Br J Dermatol. 2013;168(6):1372–4.PubMedCrossRef

Urbina F, Cristóbal MC, Sandoval R. Mal de Meleda. Cutis. 1995;56(4):235–8.

10.

Zhang J, Cheng R, Ni C, et al. First Mal de Meleda report in Chinese Mainland: two families with a recurrent homozygous missense mutation in SLURP-1. J Eur Acad Dermatol Venereol. 2015. doi:10.1111/jdv.13038.

11.

Nellen RG, Claessens T, Subramaniam R, et al. A novel mutation in SLURP1 in patients with mal de Meleda from the Indian subcontinent. J Dermatol Sci. 2015. doi:10.1016/j.jdermsci.2015.07.013.

12.

Taylor JA, Bondavalli D, Monif M, et al. Mal de Meleda in Indonesia: mutations in the SLURP1 gene appear to be ubiquitous. Australas J Dermatol. 2014. doi:10.1111/ajd.12239.

13.

Brambilla L, Pigatto PD, Boneschi V, et al. Unusual cases of Meleda keratoderma treated with aromatic retinoid etretinate. Dermatologica. 1984;168(6):283–6.PubMedCrossRef

14.

Sakabe J, Kabashima-Kubo R, Kubo A, et al. A Japanese case of Mal de Meleda with SLURP1 mutation. J Dermatol. 2014;41(8):764–5.PubMedCrossRef

15.

Chotzen VA, Starr JC, Mauro TM. Mal de Meleda in a Laotian family. Int J Dermatol. 1993;32(8):602–4.PubMedCrossRef

16.

Bchetnia M, Bozgia M, Laroussi N, et al. The first Mal de Meleda case in Libya: identification of a SLURP1 mutation. Int J Dermatol. 2014. doi:10.1111/ijd.12373.PubMed

17.

Wajid M, Kurban M, Shimomura Y, et al. Mutations in the SLURP-1 gene underlie Mal de Meleda in three Pakistani families. J Dermatol Sci. 2009;56(1):27–32.PubMedCrossRef

18.

Lestringant GG, Halawani NA, Zagzouk F. Mal de Meleda. Int J Dermatol. 1989;28(4):277–8.PubMedCrossRef

19.

Lestringant GG, Frossard PM, Adeghate E, et al. Mal de Meleda: a report of four cases from the United Arab Emirates. Pediatr Dermatol. 1997;14(3):186–91.

20.

Schnyder UW, Franceschetti AT, Ceszarovic B, et al. Autochthonous Meleda disease. Ann Dermatol Syphiligr (Paris). 1969;96(5):517–30.PubMed

21.

Ayman T, Yerebakan O, Yilmaz E. Mal de Meleda: a review of Turkish reports. J Dermatol. 2000;27(10):664–8.PubMedCrossRef

22.

Marrakchi Z, Marrachi S, Meziou TJ, et al. Mal de Meleda. 16 cases. Tunis Med. 2006;84(7):423–6.PubMed

23.

Morais e Silva FA, Cunha TV, Boeno Edos S, et al. Mal de Meleda: a report of two cases of familial occurrence. An Bras Dermatol. 2011;86(4 Suppl 1):S100–3.

24.

Nath A, Chaudhuri S, Mohan Thappa D. Mal de Meleda with lip involvement: a report of two cases. Indian J Dermatol. 2012;57(5):390–3.PubMedPubMedCentralCrossRef

25.

Lestringant GG, Hadi SM, Qayed KI, et al. Mal de Meleda: recessive transgressive palmoplantar keratoderma with three unusual facultative features. Dermatology. 1992;184(1):78–82.PubMedCrossRef

26.

Sartore L, Bordignon M, Bassetto F, et al. Melanoma in skin affected with keratoderma palmoplantaris hereditaria (Mal de Meleda): treatment with excision and grafting. J Am Acad Dermatol. 2009;61(1):161–3.PubMedCrossRef

27.

Mozzillo N, Nunziata CA, Caracò C, et al. Malignant melanoma developing in an area of hereditary palmoplantar keratoderma (Mal de Meleda). J Surg Oncol. 2003;84(4):229–33.PubMedCrossRef

28.

Tjiu JW, Lin PJ, Wu WH, et al. SLURP1 mutation-impaired T-cell activation in a family with mal de Meleda. Br J Dermatol. 2011;164(1):47–53.PubMedCrossRef

29.

Bouadjar B, Benmazouzia S, Prud’homme J, et al. Clinical and genetic studies of 3 large, consanguineous, Algerian families with Mal de Meleda. Arch Dermatol. 2000;136(10):1247–52.PubMedCrossRef

30.

Rajashekhar N, Moideen R. Palmoplantar keratoderma—Mal de Meleda syndrome. Int J Dermatol. 1997;36(11):854–6.PubMedCrossRef

31.

Hansen R, Schachner L. Pediatric dermatology. 4th ed. London: Elsevier Health Sciences; 2011.

32.

Gruber R, Hennies HC, Romani N, et al. A novel homozygous missense mutation in SLURP1 causing Mal de Meleda with an atypical phenotype. Arch Dermatol. 2011;147(6):748–50.PubMedCrossRef

33.

Fischer J, Bouadjar B, Heilig R, et al. Mutations in the gene encoding SLURP-1 in mal de Meleda. Hum Mol Genet. 2001;10:875–80.PubMedCrossRef

34.

Eckl KM, Stevens HP, Lestringant GG, et al. Mal de Meleda (MDM) caused by mutations in the gene for SLURP-1 in patients from Germany, Turkey, Palestine, and the United Arab Emirates. Hum Genet. 2003;112(1):50–6.PubMedCrossRef

35.

Charfeddine C, Mokni M, Ben Mousli R, et al. A novel missense mutation in the gene encoding SLURP-1 in patients with mal de Meleda from northern Tunisia. Br J Dermatol. 2003;149:1108–15.PubMedCrossRef

36.

Nellen RG, van Geel M, Steijlen PM, et al. Compound heterozygosity for ARS component B mutations in a Dutch patient with mal de Meleda. Br J Dermatol. 2009;160(4):878–80.PubMedCrossRef

37.

Nellen RG, Steijlen PM, van Geel M, et al. Comment on Zhao et al. “Palmoplantar keratoderma of the Gamborg-Nielsen type is caused by mutations in the SLURP1 gene and represents a variant of mal de meleda” [letter]. Acta Derm Venereol. 2015. doi:10.2340/00015555-2196.

38.

Muslumanoglu MH, Saracoglu N, Cilingir O, et al. A novel mutation in the ARS (component B) gene encoding SLURP-1 in a Turkish family with mal de Meleda. Br J Dermatol. 2006;155:467–9.PubMedCrossRef

39.

Yerebakan O, Hu G, Yilmaz E, Celebi JT. A novel mutation in the ARS (component B) gene encoding SLURP-1 in a family with Mal de Meleda. Clin Exp Dermatol. 2003;28:542–4.PubMedCrossRef

40.

Marrakchi S, Audebert S, Bouadjar B, et al. Novel mutations in the gene encoding secreted lymphocyte antigen-6/urokinase-type plasminogen activator receptor-related protein-1 (SLURP-1) and description of five ancestral haplotypes in patients with Mal de Meleda. J Invest Dermatol. 2003;120:351–5.PubMedCrossRef

41.

Favre B, Plantard L, Aeschbach L, et al. SLURP1 is a late marker of epidermal differentiation and is absent in Mal de Meleda. Invest Dermatol. 2007;127(2):301–8.CrossRef

42.

Arredondo J, Chernvavsky AI, Webber RJ, et al. Biological effects of SLURP-1 on human keratinocytes. J Invest Dermatol. 2005;125(6):1236–41.PubMedCrossRef

43.

Grando SA, Pittelkow MR, Schallreuter KU. Adrenergic and cholinergic control in the biology of epidermis: physiological and clinical significance. J Invest Dermatol. 2006;126(9):1948–65.PubMedCrossRef

44.

Chimienti F, Hogg RC, Plantard L, et al. Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of Mal de Meleda. Hum Mol Genet. 2003;12(22):3017–24.PubMedCrossRef

45.

Braun-Falco M. Hereditary palmoplantar keratodermas. J Dtsch Dermatol Ges. 2009;7(11):971–84 (quiz 984–985).

46.

Kastl I, Anton-Lamprecht I, Gamborg Nielsen P. Hereditary palmoplantar keratosis of the Gamborg Nielsen type. Clinical and ultrastructural characteristics of a new type of autosomal recessive palmoplantar keratosis. Arch Dermatol Res. 1990;282(6):363–70.PubMedCrossRef

47.

Ragunatha S, Ramesh M, Anupama P, et al. Papillon-Lefèvre syndrome with homozygous nonsense mutation of cathepsin C gene presenting with late-onset periodontitis. 2015;32(2):292–94.

48.

Online Mendelian Inheritance in Man, OMIM^®. Papillon-Lefevre syndrome; PALS. MIM number: 245000. Baltimore: Johns Hopkins University; 2014. http://www.omim.org/entry/245000. Accessed 20 July 2015.

49.

Kubo A, Shiohama A, Sasaki T, et al. Mutations in in SERPINB7, encoding a member of the serine protease inhibitor superfamily, cause Nagashima-type palmoplantar keratosis. Am J Hum Genet. 2013;93(5):945–56.PubMedPubMedCentralCrossRef

50.

Athanikar SB, Inamadar AC, Palit A, et al. Greither’s disease. Indian J Dermatol Venereol Leprol. 2003;69(4):292–93.

51.

Duchatelet S, Hovnanian A. Olmsted syndrome: clinical, molecular and therapeutic aspects. Orphanet J Rare Dis. 2015;17(10):33.CrossRef

52.

Wirtz M, Frank J. Costello syndrome: a rare RASopathy with cutaneous symptoms. Hautarzt. 2015;66(4):225–8.PubMedCrossRef

53.

Sybert VP, Dale BA, Holbrook KA. Palmoplantar keratodermas: a clinical ultrastructural and biochemical study. J Am Acad Dermatol. 1998;18:75–86.CrossRef

54.

Küster W, Reis A, Hennies HC. Epidermolytic palmoplantar keratoderma of Vörner: re-evaluation of Vörner’s original family and identification of a novel keratin 9 mutation. Arch Dermatol Res. 2002;294(6):268–72.PubMedCrossRef

55.

Livingston RJ, Sybert VP, Smith L. Expression of a truncated keratin 5 may contribute to severe palmar–plantar hyperkeratosis in epidermolysis bullosa simplex patients. J Invest Dermatol. 2001;116(6):970–4.PubMedCrossRef

56.

Lind L, Lundstrom A, Hofer P-A, Holmgren G. The gene for diffuse palmoplantar keratoderma of the type found in northern Sweden is localized to chromosome 12q11-q13. Hum Mol Genet. 1994;3:1789–93.PubMedCrossRef

57.

Hunt DM, Rickman L, Whittock NV, et al. Spectrum of dominant mutations in the desmosomal cadherin desmoglein 1, causing the skin disease striate palmoplantar keratoderma. Eur J Hum Genet. 2001;9:197–203.PubMedCrossRef

58.

Smith FJD, Hansen CD, Hull PR, et al. Pachyonychia congenita. 2006 Jan 27 [Updated 2014 Jul 24]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews^® [Internet]. Seattle: University of Washington, Seattle; 1993–2015. http://www.ncbi.nlm.nih.gov/books/NBK1280/. Accessed 26 July 2015.

59.

Mevorah B, Goldberg I, Sprecher E, et al. Olmsted syndrome: mutilating palmoplantar keratoderma with periorificial keratotic plaques. J Am Acad Dermatol. 2005;53:S266–72.PubMedCrossRef

60.

Nockemann PF. Erbliche Hornhautverdickung mit Schnuerfurchen an Fingern und Zehen und Innenohrschwerhoerigkeit. Med Welt. 1961;2:1894–900.

61.

Maestrini E, Monaco AP, McGrath JA, et al. A molecular defect in loricrin, the major component of the cornified cell envelope, underlies Vohwinkel’s syndrome. Nat Genet. 1996;13:70–7.PubMedCrossRef

62.

Kerr B, Delrue MA, Sigaudy S, et al. Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J Med Genet. 2006;43:401–5.PubMedPubMedCentralCrossRef

63.

Online Mendelian Inheritance in Man, OMIM^®. Ectodermal dysplasia/skin fragility syndrome. MIM number: 604536. Baltimore: Johns Hopkins University; 2014. http://www.omim.org/entry/604536. Accessed 26 July 2015.

64.

Itin PH, Fistarol SK. Palmoplantar keratodermas. Clin Dermatol. 2005:23(1):15–22.

65.

Toomes C, James J, Wood AJ, et al. Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis. Nat Genet. 1999;23:421–4.PubMedCrossRef

66.

Tallab TM. Richner-Hanhart syndrome: importance of early diagnosis and early intervention. J Am Acad Dermatol. 1996;35:857–9.PubMedCrossRef

67.

Barker JNWN, Protonatorios N, Tsatopoulou A, et al. Palmoplantar keratoderma, curly hair and endomyocardial fibrodysplasia: a new syndrome. Br J Dermatol. 1988;119(suppl. 33):13–4.CrossRef

68.

Carvajal-Huerta L. Epidermolytic palmoplantar keratoderma with woolly hair and dilated cardiomyopathy. J Am Acad Dermatol. 1998;39:418–21.PubMedCrossRef

69.

National Center for Biotechnology Information. GTR Genetic Testing Registry. SLURP1. Bethesda: US National Library of Medicine; 2015. http://www.ncbi.nlm.nih.gov/gtr/tests/?term=SLURP1. Accessed 21 Sept 2015.

70.

Adeyo O, Allan BB, Barnes RH 2nd, et al. Palmoplantar keratoderma along with neuromuscular and metabolic phenotypes in Slurp1-deficient mice. J Invest Dermatol. 2014;134(6):1589–98.PubMedPubMedCentralCrossRef

71.

Turgut S, Ergin S, Turgut G, et al. The role of essential and non-essential elements in Mal de Meleda. J Basic Clin Physiol Pharmacol. 2007;18(1):11–9.PubMedCrossRef

72.

Brunner MJ. Mal de Meleda; report of a case and results of treatment with vitamin A. Arch Derm Syphilol. 1950;61(5):820–3.PubMedCrossRef

73.

Reed ML, Stanley J, Stengel F, et al. Mal de Meleda treated with 13-cis retinoic acid. Arch Dermatol. 1979;115(5):605–8.PubMedCrossRef

74.

Stina-Schiller S, Seebode C, Hennies HC, et al. Palmoplantar keratoderma (PPK): acquired and genetic causes of a not so rare disease. J Dtsch Dermatol Ges. 2014;12(9):781–8.

75.

Marchac A, Blanchet-Bardon C, Revol M, et al. Surgical treatment of keratosis palmaris in Mal de Meleda. Ann Chir Plast Esthet. 2009;54(2):152–5.PubMedCrossRef

Titel: Mal de Meleda: A Focused Review
verfasst von: Caroline Perez
Amor Khachemoune
Publikationsdatum: 01.02.2016
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 1/2016
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-015-0157-1

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials

Second Primary Malignancies in CTCL Patients from 1992 to 2011: A SEER-Based, Population-Based Study Evaluating Time from CTCL Diagnosis, Age, Sex, Stage, and CD30+ Subtype

US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey

Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review

Treatments for Cutaneous Lichen Planus: A Systematic Review and Meta-Analysis